The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...

The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

The US Food and Drug Administration has approved fitusiran for bleeding prophylaxis in hemophilia A and B with or without ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

FDA approves Sanofi's Qfitlia, the first antithrombin-lowering therapy for hemophilia A or B, reducing bleeding episodes with ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

FDA approves Sanofi's Qfitlia for hemophilia A & B, reducing bleeding rates. Learn about its benefits, risks, and market ...

Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...

Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.